Highly specific, NIR fluorescent contrast agent with emission controlled by gold nanoparticle

Jianting Wang, Martin O'Toole, Archna Massey, Souvik Biswas, Michael Nantz, Samuel Achilefu, Kyung A. Kang

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Nanoparticles are currently being intensively studied for in vivo molecular imaging because of their unique and beneficial properties. Among these particles, some metal particles possess strong surface plasmon fields that can effectively alter fluorescence. Using this fluorescence alteration, an NIR fluorophore based, nanosized contrast agent for breast cancer diagnosis is being developed. The fluorophore is conjugated to gold nanoparticles (GNP) viaa short spacer whose lengthwas specially adjusted to have the strong plasmon field to quench the fluorescence. The spacer also has a special molecular sequence that can be cleaved by an enzyme secreted by targeted cancer cells. Normally, the entity does not fluoresce. If it is delivered to the cancer site, the short spacer would be cleaved by the enzyme secreted by the cancer cell at which point the fluorescence would be restored. This entity can incorporate a cancer targeting molecule for a cancer specific delivery. The entity specifically targets cancer cells and fluoresce only when the spacer is cleaved by a specific cancer secreting biomolecule, providing dual specificity for cancer diagnosis. In the future, this entity will be combined with cancer drugs for seamless detection and personalized therapy.

Original languageEnglish (US)
Title of host publicationAdvances in Experimental Medicine and Biology
Pages149-154
Number of pages6
Volume701
DOIs
StatePublished - 2011
Externally publishedYes

Publication series

NameAdvances in Experimental Medicine and Biology
Volume701
ISSN (Print)00652598

Fingerprint

Fluorescent Dyes
Gold
Nanoparticles
Contrast Media
Fluorescence
Fluorophores
Cells
Neoplasms
Molecular imaging
Biomolecules
Enzymes
Metals
Molecules
Molecular Imaging
Pharmaceutical Preparations
Breast Neoplasms

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Wang, J., O'Toole, M., Massey, A., Biswas, S., Nantz, M., Achilefu, S., & Kang, K. A. (2011). Highly specific, NIR fluorescent contrast agent with emission controlled by gold nanoparticle. In Advances in Experimental Medicine and Biology (Vol. 701, pp. 149-154). (Advances in Experimental Medicine and Biology; Vol. 701). https://doi.org/10.1007/978-1-4419-7756-4-21

Highly specific, NIR fluorescent contrast agent with emission controlled by gold nanoparticle. / Wang, Jianting; O'Toole, Martin; Massey, Archna; Biswas, Souvik; Nantz, Michael; Achilefu, Samuel; Kang, Kyung A.

Advances in Experimental Medicine and Biology. Vol. 701 2011. p. 149-154 (Advances in Experimental Medicine and Biology; Vol. 701).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Wang, J, O'Toole, M, Massey, A, Biswas, S, Nantz, M, Achilefu, S & Kang, KA 2011, Highly specific, NIR fluorescent contrast agent with emission controlled by gold nanoparticle. in Advances in Experimental Medicine and Biology. vol. 701, Advances in Experimental Medicine and Biology, vol. 701, pp. 149-154. https://doi.org/10.1007/978-1-4419-7756-4-21
Wang J, O'Toole M, Massey A, Biswas S, Nantz M, Achilefu S et al. Highly specific, NIR fluorescent contrast agent with emission controlled by gold nanoparticle. In Advances in Experimental Medicine and Biology. Vol. 701. 2011. p. 149-154. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/978-1-4419-7756-4-21
Wang, Jianting ; O'Toole, Martin ; Massey, Archna ; Biswas, Souvik ; Nantz, Michael ; Achilefu, Samuel ; Kang, Kyung A. / Highly specific, NIR fluorescent contrast agent with emission controlled by gold nanoparticle. Advances in Experimental Medicine and Biology. Vol. 701 2011. pp. 149-154 (Advances in Experimental Medicine and Biology).
@inproceedings{28b8ef77bbf14113b773703817a38f9f,
title = "Highly specific, NIR fluorescent contrast agent with emission controlled by gold nanoparticle",
abstract = "Nanoparticles are currently being intensively studied for in vivo molecular imaging because of their unique and beneficial properties. Among these particles, some metal particles possess strong surface plasmon fields that can effectively alter fluorescence. Using this fluorescence alteration, an NIR fluorophore based, nanosized contrast agent for breast cancer diagnosis is being developed. The fluorophore is conjugated to gold nanoparticles (GNP) viaa short spacer whose lengthwas specially adjusted to have the strong plasmon field to quench the fluorescence. The spacer also has a special molecular sequence that can be cleaved by an enzyme secreted by targeted cancer cells. Normally, the entity does not fluoresce. If it is delivered to the cancer site, the short spacer would be cleaved by the enzyme secreted by the cancer cell at which point the fluorescence would be restored. This entity can incorporate a cancer targeting molecule for a cancer specific delivery. The entity specifically targets cancer cells and fluoresce only when the spacer is cleaved by a specific cancer secreting biomolecule, providing dual specificity for cancer diagnosis. In the future, this entity will be combined with cancer drugs for seamless detection and personalized therapy.",
author = "Jianting Wang and Martin O'Toole and Archna Massey and Souvik Biswas and Michael Nantz and Samuel Achilefu and Kang, {Kyung A.}",
year = "2011",
doi = "10.1007/978-1-4419-7756-4-21",
language = "English (US)",
isbn = "9781441977557",
volume = "701",
series = "Advances in Experimental Medicine and Biology",
pages = "149--154",
booktitle = "Advances in Experimental Medicine and Biology",

}

TY - GEN

T1 - Highly specific, NIR fluorescent contrast agent with emission controlled by gold nanoparticle

AU - Wang, Jianting

AU - O'Toole, Martin

AU - Massey, Archna

AU - Biswas, Souvik

AU - Nantz, Michael

AU - Achilefu, Samuel

AU - Kang, Kyung A.

PY - 2011

Y1 - 2011

N2 - Nanoparticles are currently being intensively studied for in vivo molecular imaging because of their unique and beneficial properties. Among these particles, some metal particles possess strong surface plasmon fields that can effectively alter fluorescence. Using this fluorescence alteration, an NIR fluorophore based, nanosized contrast agent for breast cancer diagnosis is being developed. The fluorophore is conjugated to gold nanoparticles (GNP) viaa short spacer whose lengthwas specially adjusted to have the strong plasmon field to quench the fluorescence. The spacer also has a special molecular sequence that can be cleaved by an enzyme secreted by targeted cancer cells. Normally, the entity does not fluoresce. If it is delivered to the cancer site, the short spacer would be cleaved by the enzyme secreted by the cancer cell at which point the fluorescence would be restored. This entity can incorporate a cancer targeting molecule for a cancer specific delivery. The entity specifically targets cancer cells and fluoresce only when the spacer is cleaved by a specific cancer secreting biomolecule, providing dual specificity for cancer diagnosis. In the future, this entity will be combined with cancer drugs for seamless detection and personalized therapy.

AB - Nanoparticles are currently being intensively studied for in vivo molecular imaging because of their unique and beneficial properties. Among these particles, some metal particles possess strong surface plasmon fields that can effectively alter fluorescence. Using this fluorescence alteration, an NIR fluorophore based, nanosized contrast agent for breast cancer diagnosis is being developed. The fluorophore is conjugated to gold nanoparticles (GNP) viaa short spacer whose lengthwas specially adjusted to have the strong plasmon field to quench the fluorescence. The spacer also has a special molecular sequence that can be cleaved by an enzyme secreted by targeted cancer cells. Normally, the entity does not fluoresce. If it is delivered to the cancer site, the short spacer would be cleaved by the enzyme secreted by the cancer cell at which point the fluorescence would be restored. This entity can incorporate a cancer targeting molecule for a cancer specific delivery. The entity specifically targets cancer cells and fluoresce only when the spacer is cleaved by a specific cancer secreting biomolecule, providing dual specificity for cancer diagnosis. In the future, this entity will be combined with cancer drugs for seamless detection and personalized therapy.

UR - http://www.scopus.com/inward/record.url?scp=79956064959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956064959&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-7756-4-21

DO - 10.1007/978-1-4419-7756-4-21

M3 - Conference contribution

C2 - 21445782

SN - 9781441977557

VL - 701

T3 - Advances in Experimental Medicine and Biology

SP - 149

EP - 154

BT - Advances in Experimental Medicine and Biology

ER -